Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Not yet recruiting1
Withdrawn1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

not_yet_recruiting125%
withdrawn125%
completed125%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_3

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

NCT07569757
completedphase_2

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

NCT02654990
terminatedphase_1

Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

NCT00923273
withdrawnphase_2

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

NCT02756663

Clinical Trials (4)

Showing 4 of 4 trials
NCT07569757Phase 3

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Not Yet Recruiting
NCT02654990Phase 2

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed
NCT00923273Phase 1

Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

Terminated
NCT02756663Phase 2

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4